カテゴリ： GlobalData, アメリカ, 企業調査

Acceleron Pharma Inc (XLRN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Acceleron Pharma Inc (XLRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010844
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Acceleron Pharma Inc (AcceleronPharma) is a clinical stage biopharmaceutical company that discovers, developsand commercializes therapeuticsto treat serious and rare diseases. The company’s lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodysplastic syndromes, beta-thalassemia and myelofibrosis. It also offers pipeline products for the treatment of facioscapulohumeral muscular dystrophy, neuromuscular diseases, renal cell carcinoma and other indications. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. AcceleronPharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc (XLRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adimab Enters into Agreement with Acceleron Pharma 11
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 12
Licensing Agreements 13
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Equity Offering 16
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 26
Acceleron Pharma Inc – Key Competitors 27
Acceleron Pharma Inc – Key Employees 28
Acceleron Pharma Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 30
May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 32
Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 34
Nov 03, 2016: Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results 36
Aug 04, 2016: Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results 38
May 05, 2016: Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results 40
Feb 25, 2016: Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights 42
Corporate Communications 45
Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 45
May 02, 2017: Acceleron Announces Management Change 46
Sep 27, 2016: Acceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor 47
Jul 25, 2016: Acceleron Pharma Appoints Thomas McCourt to its Board of Directors 48
Product News 49
11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 49
05/19/2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association 50
Clinical Trials 51
Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 51
Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 52
Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 53
Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 54
Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 55
Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 56
Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 57
Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 59
Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 61
May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 62
May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 63
Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 65
Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 66
Dec 05, 2016: Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology 67
Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology 68
Dec 04, 2016: Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology 69
Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association 70
Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association 72
Other Significant Developments 74
Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acceleron Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adimab Enters into Agreement with Acceleron Pharma 11
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 12
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 26
Acceleron Pharma Inc, Key Competitors 27
Acceleron Pharma Inc, Key Employees 28

★海外企業調査レポート[Acceleron Pharma Inc (XLRN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • 84 Lumber Company：企業の戦略・SWOT・財務分析
    84 Lumber Company - Strategy, SWOT and Corporate Finance Report Summary 84 Lumber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Arcus Biosciences Inc (RCUS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Arcus Biosciences Inc (Arcus Biosciences) is a clinical stage bio-pharmaceutical company. The company develops and commercializes cancer immunotherapies. Its product pipeline includes AB928, which is in phase 1/1b trial; AB122 is being developed for cancer patients, is in Phase 1 trial; AB15 …
  • Academia Sinica-製薬・医療分野：企業M&A・提携分析
    Summary Academia Sinica is an academic institution that promotes and undertakes research activities in the disciplines of mathematics and physical sciences, life sciences, and humanities and social sciences. The institution integrates research activities to improve the planning, implementation, and …
  • China Communications Construction Co Ltd：企業の戦略・SWOT・財務情報
    China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Total E&P Canada Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Total E&P Canada Ltd (Total E&P Canada), a subsidiary of Total S.A. is an oil and gas company that offers exploration and production of oil and gas properties. The company has assets in Alberta’s Athabasca Oil Sands region, which include Surmont, Northern Lights, Fort Hills and Joslyn North …
  • Carna Biosciences Inc (4572)：製薬・医療：M&Aディール及び事業提携情報
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • Clean Harbors Inc (CLH)：企業の財務・戦略的SWOT分析
    Clean Harbors Inc (CLH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • 2020 GeneSystems Inc-製薬・医療分野：企業M&A・提携分析
    Summary 20/20 GeneSystems Inc (20/20 Gene) is a medical diagnostic company that develops and commercializes diagnostic tests and proteomics products for early disease detection, therapy selection and biodefense applications. The company provides tests in the areas such as personalized medicine, earl …
  • Northrop Grumman Aerospace Systems：企業の戦略・SWOT・財務情報
    Northrop Grumman Aerospace Systems - Strategy, SWOT and Corporate Finance Report Summary Northrop Grumman Aerospace Systems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Indiana Resources Limited：企業の戦略・SWOT・財務情報
    Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Murphy Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Murphy Oil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Murphy Oil Corp (Murphy) is an international independent oil and gas exploration and production company. It explores for and produces crude oil, natural gas, and natural gas liquids. The company oper …
  • NGEx Resources Inc：企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Genmab AS (GMAB)：企業の財務・戦略的SWOT分析
    Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Heritage Provider Network Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Heritage Provider Network Inc (HPN) is a managed care organization that offers medical care services. The organization operates through medical care group, urgent care centers and affiliated health plans. It offers patient care services such as urgent care, pharmacy, lab, radiology, pediatri …
  • Belfius Bank Sa：企業の戦略・SWOT・財務分析
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Aavin Equity Advisors, LLC：企業の戦略・SWOT・財務分析
    Aavin Equity Advisors, LLC - Strategy, SWOT and Corporate Finance Report Summary Aavin Equity Advisors, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Entersoft SA (ENTER)：企業の財務・戦略的SWOT分析
    Entersoft SA (ENTER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PIK-Group：企業のM&A・事業提携・投資動向
    PIK-Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PIK-Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • OBB-Infrastruktur AG：企業の戦略的SWOT分析
    OBB-Infrastruktur AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Banco de Chile：企業の戦略・SWOT・財務情報
    Banco de Chile - Strategy, SWOT and Corporate Finance Report Summary Banco de Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆